MRI Scans to Guide Radiation Treatment for Head and Neck Cancer
Tests repeated MRI scans during radiation in adults with head and neck cancer.
Plain-language title generated from the registry record
Registry title: HN-QUEST: A Study of Head and Neck Imaging Biomarkers
Key facts
- Where
- Toronto, CanadaSee the site
Where in Canada
- Princess Margaret Cancer CentreToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT05919290
- Record updated
- 5 March 2026
- Original description
This is a multi arm, single center, investigator initiated study to investigate online adaptive radiotherapy and biomarker development in patients with newly diagnosed HNSCC (Head and Neck Squamous Cell Carcinoma) receiving curative therapy.Read full original descriptionShow less
HN QUEST- Evaluation of Online MRgRT and Repeat Functional Imaging in Patients Undergoing Curative (CT)RT for HN Malignancy
This is a multi arm, single center, investigator initiated study to investigate online adaptive radiotherapy and biomarker development in patients with newly diagnosed HNSCC (Head and Neck Squamous Cell Carcinoma) receiving curative therapy.
The study will consist of two prospective arms. In Arm 1 up to 100 HNSCC patients receiving (CT)RT (computed tomography-based radiation therapy) will receive up to weekly non-contrast MRI (magnetic resonance imaging) scans during treatment. Arm 2 consists of two cohorts. In cohort A up to 20 healthy volunteers will undergo non-contrast MRI at two time points. In cohort B up to 53 patients planned to receive curative (chemo) radiotherapy for HNSCC will undergo two baseline MRI scans, one MRI in week 2 and week 4, and final MRI scan 6-8 weeks after completion of treatment.
Inclusion: Age >/= 18 years; Histologically proven Head and Neck Squamous Cell carcinoma; Primary or nodal disease > 3cm for biomarker imaging; Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; Planned for curative surgery or (chemo)radiotherapy; Willingness to undergo repeat MRI; Able to receive and understand verbal and written information regarding study and able to give written informed consent; Adequate renal function: Calculated creatinine clearance >/= 30ml/min; Be able to lie comfortably on back for 1 hour; Age >/= 18 years; Able to receive and understand verbal and written information regarding study and able to give written informed consent; Willingness to undergo repeat MRI.
Exclusion: Previous solid tumor treated within last 5 years; As judged by investigator evidence of systemic disease that makes unsuitable for study; History of significant obstructive airway disease; History of gadolinium contrast allergy; Underlying significant respiratory disease; Contra-indication for serial MRI scans; Pregnancy; Unwillingness to sign informed consent; Contra-indication for MRI.